en · de · es · fr · pt
melanotan-2-notes.peptides4088.com › Guide › Background And Chemical Profile — Common Mistakes

Background And Chemical Profile — Common Mistakes

By Editorial Desk · published 2025-11-05 · last reviewed 2025-12-09 · Guide

This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-12-09 and is reviewed periodically as new material appears.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Related pages on this site

Background and Mechanism of Melanotan-2

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Reference notes

Hahn remained modest and informal all his life. His disarming frankness, unfailing kindness, good common sense, and impish humour will be remembered by his many friends all over the world. The Royal Society in London wrote in an obituary:

== Names of the proposed state == In the August 1991 draft of the treaty, the proclaimed name for the new country was the Union of Soviet Sovereign Republics (Russian: Союз Советских Суверенных Республик, romanized: Soyuz Sovetskikh Suverennykh Respublik). This would conserve the Russian "СССР" acronym, meaning "USSR" and "Soviet Union" in English and other languages. By September 1991, support for continuing the Soviet system had transitioned into reforming the Soviet Union into a confederation of sovereign states. The final draft renamed the proposed state as the Union of Sovereign States (Russian: Союз Суверенных Государств, romanized: Soyuz Suverennykh Gosudarstv).

He convened researchers from the diverse fields converging on this newly recognized family of receptors and proposed a unifying nomenclature. Springer described the first sequence relationships among family members and was the first to use an αβ nomenclature in which α subunits were named after their receptor, such as αL for LFA-1 and αM for Mac-1. However, because the meeting was focused on fibronectin, the fibronectin receptor was designated α5β1, conferring the β1 designation on the subunit that pairs with more α subunits than any other β subunit in the family. The ones discovered by Springer on white blood cells became the β2 integrins. Contributions by Springer, Hynes, and Ruoslahti to the integrin field were recognized by the 2022 Lasker Basic Medical Research Award.

239Pu, a fissile isotope that is the second most used nuclear fuel in nuclear reactors after uranium-235, and the most used fuel in the fission portion of nuclear weapons, is produced from uranium-238 by neutron capture followed by two beta decays. 240Pu, 241Pu, and 242Pu are produced by further neutron capture. The odd-mass isotopes 239Pu and 241Pu have about a 3/4 chance of undergoing fission on capture of a thermal neutron and about a 1/4 chance of retaining the neutron and becoming the next heavier isotope. The even-mass isotopes are fertile but not fissile and also have a lower probability (cross section) of neutron capture; therefore, they tend to accumulate in nuclear fuel used in a thermal reactor, the design of nearly all nuclear power plants today. In plutonium that has been used a second time in thermal reactors in MOX fuel, 240Pu may even be the most common isotope. All plutonium isotopes and other actinides, however, are fissionable with fast neutrons. 240Pu does have a moderate thermal neutron absorption cross section, so that 241Pu production in a thermal reactor becomes a significant fraction as large as 239Pu production. 241Pu has a half-life of 14 years, and has slightly higher thermal neutron cross sections than 239Pu for both fission and absorption. While nuclear fuel is being used in a reactor, a 241Pu nucleus is much more likely to fission or to capture a neutron than to decay. 241Pu accounts for a significant portion of fissions in thermal reactor fuel that has been used for some time.

Sources: en.wikipedia.org

Reference notes

== History == 1. FC Lokomotive Leipzig claims to be the successor to the VfB Leipzig and SC Sportbrüder Leipzig teams, established in 1896 and 1893, respectively, and therefore, one of the oldest clubs of the German Football Association. However, they are not nominal successors. In 2018, 1. FC Lokomotive announced a merger with the formally extant but dormant VfB Leipzig in order to be entitled to the forerunner's titles. Due to the significant breaks and turmoil in the club's history, especially during the post-World War II era, their exact establishment date remains a source of contention.

The rapid development of synthetic dyes in the late nineteenth century stems from the rise of industrial research laboratories in Germany, where firms such as BASF and Hoechst used university-trained chemists, designed new processes, and pioneered breakthroughs in synthetic coloring. With over 10 laboratories established between 1880 and 1890, scientists had formalized research practices and contributed to advances in dye chemistry through organized experimentation and chemical design, and made Germany a global leader in synthetic dye manufacturing. The 20th century was again characterized by increases in scope and scale of chemical production. Pigments like cadmium selenide, manganese blue, molybdenum red, and bismuth vanadate were synthesized. High purity titanium dioxide and zinc oxide were produced for the first time on an industrial scale and introduced synthetic white pigments. The first insoluble organic pigments, the red naphthols, containing neither acid nor basic groups, were produced and sold. Furthermore, the quality of the new dyes increased. Chemist Rene Bohn developed a brilliant blue vat dye, indanthrone, with excellent color fastness in 1901. BASF(Badische Anilin und Soda Fabrik), the largest manufacturer of vat dyes, sold it as Indanthren Blue RS, along with the synthetic indigo they placed on the market in 1897. Allegedly James Morton, a leader in England's textile industry, was out walking when he saw some tapestries he produced using aniline dyes had already faded, despite only recently being put on display.

Small humanin-like peptides (SHLPs) are a group of peptides encoded in the 16S ribosomal RNA region of mitochondrial genome. Six peptides of this group (SHLP1–6) have been identified so far, between 20-38 amino acids in length. They are derived from the mitochondria and act as important retrograde signaling molecules in the cell. Their names were given because the SHLPs share some similar biological effects with the mitochondrial peptide Humanin. Every individual SHLP showed unique expression pattern in mouse tissues. Specifically, SHLP1 was detected in the heart, kidney, and spleen; SHLP2 was detected in the liver, kidney, and muscle; SHLP3 was detected in the brain and spleen; SHLP4 was detected in the liver and prostate; and SHLP6 was detected in the liver and kidney. Experiments using cultured mammalian cells have shown that SHLPs are bioactive peptides. Incubation of each synthetic SHLP with cells affected cell viability, proliferation and apoptosis differentially, which suggests that every SHLP may play a different role in the biological system.

==== Neuropathology ==== In the peripheral nervous system, the most common problem is the failure of nerve conduction, which can be due to different causes including diabetic neuropathy and demyelinating disorders such as multiple sclerosis and amyotrophic lateral sclerosis.

Like many other medical conditions, obesity is the result of an interplay between genetic and environmental factors. Polymorphisms in various genes controlling appetite and metabolism predispose to obesity when sufficient food energy is present. Advances in genome-wide association studies (GWAS) have since identified substantially more genomic loci linked to obesity susceptibility than were known in 2006, though the relative contribution of each remains an active area of research. People with two copies of the FTO gene (fat mass and obesity associated gene) have been found on average to weigh 3–4 kg more and have a 1.67-fold greater risk of obesity compared with those without the risk allele. The differences in BMI between people that are due to genetics varies depending on the population examined from 6% to 85%. Obesity is a major feature in several syndromes, such as Prader–Willi syndrome, Bardet–Biedl syndrome, Cohen syndrome, and MOMO syndrome. (The term "non-syndromic obesity" is sometimes used to exclude these conditions.) In people with early-onset severe obesity (defined by an onset before 10 years of age and body mass index over three standard deviations above normal), 7% harbor a single point DNA mutation. Studies that have focused on inheritance patterns rather than on specific genes have found that 80% of the offspring of two obese parents were also obese, in contrast to less than 10% of the offspring of two parents who were of normal weight. Different people exposed to the same environment have different risks of obesity due to their underlying genetics.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

Network